Accepted Manuscripts                   Back to the articles list | Back to browse issues page

XML Print


Abstract:   (240 Views)
Introduction: Psychomotor slowing and reduced mental flexibility are symptoms of cognitive decline that can occur in type 2 diabetes disease (TD2). Strategies that combine the control of hyperglycaemia with prevention of cognitive decline are desirable. Thus, this study reports the effect of naringin on cognitive deficit in diabetic rats.
 
Methods: TD2 in Wistar rats was induced with nicotinamide/streptozotocin (NA/STZ). Naringin (50 and 100 mg/kg p.o) or Glibenclamide (5 mg/kg) was administered for 30 days to diabetic rats.  Cognitive performance was investigated by using the Morris water maze. Serum glucose, lipid profiles, brain tumour necrosis factor alpha and acetylcholinesterase (AChE) activity were determined.
 
Results: Naringin and glibenclamide significantly reduced the escape latency, increased the time spent in the correct quadrant and number of entries in diabetic rats. Also, naringin reduced blood glucose, serum cholesterol, low-density lipoprotein cholesterol levels, triglycerides, and prevented a decrease in the level of high-density lipoprotein cholesterol, in diabetic rats. Naringin and glibenclamide treated diabetic rats showed a significant low levels of AChE activity and tumour necrosis factor alpha.
 
Conclusion: Naringin ameliorates diabetes induced cognitive deficit via reduction of inflammation, hyperglycaemia, hyperlipidaemia, and acetylcholinesterase (AChE) activity.
     
Types of Manuscript: Original Research | Subject: Pharmacology

attachement [PDF 692 KB]  (10 Download)
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.